Great news for MSB today as well, 100 day survival data in their paediatric phase 3 GVHD trial. Overall survival after 100 days of 75%. Smaller numbers in the CYP studies being phase 1, but definitely promising greater efficacy.... Good luck to MSB with getting their product to market, hopefully CYP won't be too far behind, at a drastically reduced cost.
Ann: Positive 28-day Clinical Trial Data in Cohort B, page-15
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.010(5.56%) |
Mkt cap ! $34.32M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.5¢ | 18.0¢ | $9.062K | 48.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 104632 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 3 | 1 |
View Market Depth
| Last trade - 14.37pm 12/09/2024 (20 minute delay) ? |
| CYP (ASX) Chart |